1. Introduction

Age related macular degeneration (AMD) is the leading cause of blindness in the developed countries. Approximately 8 million people in America have AMD and the number of advanced AMD is likely to rise by 50% by year 2020 due to the projected increase in the number of elderly people (Friedman et al., 2004). AMD is a condition of significant morbidity in terms of both physical and mental health (Hassell et al 2006). The burden of this disease is multifaceted as both the individual and society bear a cost. The individual has a loss of independence and ability of self care, with a pressure on society to fulfil the need for community and vision related support.

In this review of AMD, we will explore the epidemiology of AMD, the criteria for diagnosis with particular focus on the pathophysiology and treatments of wet AMD.

1.1 Epidemiology

AMD affects a large proportion of the elderly population. By applying the criteria of presence of macular drusen greater than 63 micrometres in diameter on fundus photography, up to 61% of adults over 60 years have some degree of AMD (Piermarocchi et al 2011). With a high estimated prevalence, it is important to understand the potential risk factors for this condition.

A meta analysis of published data suggests that increasing age, current cigarette smoking, previous cataract surgery, and a family history of AMD show strong and consistent associations with late AMD. Risk factors with moderate and consistent associations were higher body mass index, history of cardiovascular disease, hypertension, and higher plasma fibrinogen. Risk factors with weaker and inconsistent associations were gender, ethnicity, diabetes, iris colour, history of cerebrovascular disease, and serum total and HDL cholesterol and triglyceride levels (Chakravarthy et al 2010).

Direct associations between AMD and age, cataract, family history, alcohol consumption, the apolipoproteins A1 and B were also found in a 14 year follow up amongst a city populations (Buch et al 2005). In addition, recent data on human genome project have linked a complement H polymorphism Try402His on chromosome 1 to increased risk of AMD (Klein et al.,2005). Ala69ser polymorphism in the ARMS2 gene on chromosome 10 is yet another instance where genetic susceptibility for this condition has been established (Rivera et al., 2005). It has also been shown that ARMS2 polymorphism together with smoking, can
synergistically increase the risk of developing AMD (Schmidt et al., 2006). Therefore it is evident that AMD is a result of interplay of genetic and environmental factors leading to the final pathology.

Better understanding of risk factors can help to identify individuals at high risk for wet AMD who may benefit from early intervention with existing or novel therapies. Using visual acuity as an outcome measure, visual prognosis is more favourable in patients with early intervention (Wong et al 2008).

1.2 Classification of AMD and diagnosis

AMD is characterized by the deposition of polymorphous material between the retinal pigmented epithelium and Bruch’s membrane (Jager et al., 2008). These depositions are named Drusen. Drusen are categorised by sizes as, small(<63μm), medium (63-124 μm) and large (>124 μm) (Bird et al., 1995). They are also considered as hard or soft depending on the appearance of their margins on ophthalmological examination. While hard drusens have clearly defined margins, soft ones have less defined and fluid margins (Bird et al., 1995).

Classically the condition is divided into two main subtypes; dry/non exudative and wet/exudative. The Age-related Eye Disease Study (AREDS) fundus photographic severity scale is one of the main classification systems used for this condition (Sallo et al 2009):

No AMD (AREDS category 1)
No or a few small (<63 micrometres in diameter) drusen.

Early AMD (AREDS category 2)
Many small drusen or a few intermediate-sized (63-124 micrometres in diameter) drusen, or macular pigmentary changes.

Intermediate AMD (AREDS category 3)
Extensive intermediate drusen or at least one large (≥125 micrometres) drusen, or geographic atrophy not involving the foveal centre.

Advanced AMD (AREDS category 4)
Geographic atrophy involving the foveal centre (atrophic, or dry AMD)

Choroidal neovascularisation (wet AMD) or evidence for neovascular maculopathy (subretinal haemorrhage, serous retinal or retinal pigment epithelium detachments, lipid exudates, or fibrovascular scar).

Wet AMD results from the abnormal growth of blood vessels from the choriocapillaris (choroidal neovascularisation), through Bruch's membrane. The fragility of the blood vessels and inflammatory processes lead to subretinal haemorrhages and fibrovascular scarring. This process can occur de novo or as a progression of dry AMD.

As with many classification systems, there is variability in AMD grading between clinicians. Therefore although such scales are important for accurate follow up of AMD progression, care is needed in their interpretation.
To classify AMD, multiple ophthalmological tools have proven to be useful including dilated indirect ophthalmoscopy, stereoscopic fundus photography, amsler grid testing, fundus fluorescein angiography (FFA) and optical coherence tomography (OCT). Of the mentioned techniques available, FFA is of great importance as it allows differentiation between neovascularisation attributable to AMD and that caused by other conditions. The use of FFA has enabled sub-classification of wet AMD according to the appearance of the lesions and the location of choroidal neovascularisation in relation to the fovea. The appearance can be described as classic or occult, which is according to the defined features of the membrane at early and late phases. The location can be extrafoveal (choroidal neovascularisation greater than 200um from the foveal avascular zone), juxtafoveal (choroidal neovascularisation is closer than 200um from the foveal avascular zone) and sub-foveal (originating or extension of choroidal neovascularisation to the centre of the avascular zone). OCT provides a cross sectional image of the macula and identifies retinal pigment detachment, fluid accumulation and vitreo-macular attachments. OCT has become an important tool in the monitoring progression of wet AMD especially in light of new therapeutic possibilities.

2. Pathophysiology of wet AMD

In this section we will explore the clinical presentation and the current pathophysiological mechanism underlying the development of AMD.

2.1 Clinical presentation of wet AMD

Clinically, AMD presents with visual loss of varying severity. Early in the course of disease, patients can present with very mild symptoms or be completely asymptomatic. Some patients, however, do experience a loss of contrast sensitivity, blurred vision and scotomas as the disease progresses to the intermediate stage (Jager et al., 2008). Other visual abnormalities associated with AMD include metamorphopsia (distortion of straight lines), disparity of image size, macropsia and micropsia, hyperopic refractive shift with associated anisometropia, light glare, floaters, photopsia (Schmidt-Erfurth et al 2004). However, neovascular or wet AMD, unlike the dry subtype, can have a sudden onset of presentation due to subretinal haemorrhages and exudates leading to retinal detachment and a acute visual loss (Jager et al., 2008). Although wet AMD is only responsible for 15% of the total AMD, it is responsible for more than 80% of AMD-related severe visual loss and blindness (Fine et al., 1986).

2.2 Pathophysiological models for AMD development

Various theories and models have been proposed to explain the pathophysiology of AMD with multiple factors contributing to the final outcome. Most models proposed focus either on the Bruch’s membrane or on the retinal pigmented cells overlying this membrane.

Retinal pigment epithelial (RPE) cells, form a single layer of cells overlying Bruch’s membrane with photoreceptors located anterior to RPE layer. RPE cells play a very complex role in preserving photoreceptors and their function. One of their major functions is to remove the shed outer segments of the photoreceptors by phagocytosis (Chang and Finnemann, 2007; Finnemann and Silverstein, 2001). It has been shown that failure of this process will result in build up of debris between the retinal layer and the Bruch’s membrane leading to retinal degeneration (Nandrot et al., 2004).
Fig. 1. Fundoscopic view—dry AMD. Note there is no neovascularisation evident.

Fig. 2. Fundoscopic view of wet AMD. Excessive neovascularisation in macular region.
Fig. 3. Fundus fluorescein angiography (FFA) image of corresponding eye affected by wet AMD.

Fig. 4. Optical coherence tomography (OCT) image of corresponding eye. Significant macular oedema is evident.
In AMD, various abnormalities in the Bruch’s membrane have been shown to lead to the disruption of RPE function (Sun et al., 2007), and this in turn can lead to the disruption of photoreceptor function and their loss. Therefore, Bruch’s membrane has been the focus of great deal of AMD research.

To understand the pathophysiology of AMD, it is necessary to understand the basic normal structure of Bruch’s membrane. Bruch’s membrane is a penta-laminar structure, composed of RPE basement membrane, inner collagenous layer, elastin lamina, outer collagenous layer and choriocapillary basement membrane (Zarbin et al 2003). Each layer has a different composition of extracellular ligands, capable of interacting with integrins on the RPE cells. The top layer of Bruch’s membrane (the RPE basement membrane) is of great importance as it contains an important extracellular matrix called laminin (Das et al., 1990; Zarbin, 2003; Pauleikhoff et al., 1990) necessary for RPE adhesion and attachment.

Over the years, molecular analysis of Bruch’s membrane has lead to the identification of composition of each layer as summarized in the table below (Das et al., 1990; Zarbin, 2003; Pauleikhoff et al., 1990).

| Layer 1. Basement membrane (Immediately underneath RPE layer) | Collagen IV, Collagen V, laminin, Heparan sulphate |
| Layer 2. Inner collagenous layer | Collagen I, Collagen III, Collagen V, fibronectin, Chondroitin sulphate, dermatan sulphate |
| Layer 3. Elastic lamina | Elastin, Collagen I, Fibronectin |
| Layer 4. Outer collagenous layer | Collagen I, Collagen III, Collagen V, fibronectin, Chondroitin sulphate, Dermatan sulphate |
| Layer 5. Choriocapillaries basement membrane | Collagen IV, Collagen V, Collagen VI, laminin, heparan sulphate |

Table 1. Matrix components of different layers of Bruch's membrane.

Each layer of Bruch's membrane is composed of mixture of proteoglycans and adhesive ligands. Adhesive ligands interact with integrins on the surface of RPE cells. Different subunits of integrins interact with different class of ligands. RPE cells attachment to Bruch's membrane is largely dependent on integrin's ability to anchor the cell to the membrane firmly. Pathological states affecting the membrane or RPE cells therefore, may disrupt this important interaction leading to loss of adhesion and death of RPE cells.

A large number of hypotheses have existed regarding pathological processes involved in AMD. Overall, the pathological mechanisms proposed in AMD can be divided into 4 categories of inflammation, oxidative stress, abnormal ECM production, formation of CNVs and neovascularisation (Zarbin, 2004). These various components can happen either sequentially or they can occur simultaneously, leading to the final outcome seen in AMD (Zarbin, 2004).

### 2.2.1 The inflammation component

Although drusen formation is one of the hallmarks of AMD, controversy exists as to whether they are directly involved in the pathology of AMD. Drusen can be found in non-AMD patient eyes incidentally associated with aging (Zarbin, 2004). However, others have
suggested that the accumulation of large numbers of macular drusen is a necessity for the development of geographic atrophy and choroidal neovascularization characteristic of advanced AMD (Harman, 1956; Wallace, 1999).

Biochemical and immunohistological studies suggest drusen consist of immunoglobulins and components of the complement pathway (such as the C5b-C9 complex), acute phase response proteins raised in inflammation (CRP, amyloid P component and alpha1-antitrypsin), proteins that modulate the immune response (such as vitronectin, clusterin, apolipoprotein E, membrane cofactor protein and complement receptor1), major histocompatibility complex class 2 antigens, and HLA-DR and cluster differentiation antigens (Hageman et al., 1999; Johnson et al., 2000; Mullins et al., 2000; Sakaguchi et al., 2002; Zarbin, 2004). In addition, there are cellular components in drusen including RPE membrane debris, lipofuscin, melanin and choroidal dendritic cells (Ishibashi et al., 1986; Killingsworth, 1987; Mullins et al., 2000).

In support of this inflammatory theory, intravitreal injections of corticosteroids reduce the incidence of laser-induced CNVs in non human primates, possibly by reducing inflammation (Ishibashi et al., 1985).

2.2.2 Oxidative stress

It has been shown that with increasing age, oxidative damage in RPE cells also increases (Wallace et al., 1998). This is associated with a decrease in levels of antioxidant protective agents such as plasma glutathione, while oxidized glutathione levels increase. Also antioxidant vitamins, such as vitamin C and E, show a decline with increasing age (Rikans and Moore, 1988; Vandewoude and Vandewoude, 1987).

In support of oxidation stress as one of the factors involved, accumulation of lipofuscin has been observed in aging eyes. Lipofuscin granules are continuously exposed to visible light and to high oxygen tension, which causes the production of reactive oxygen species and oxidative damage to RPE cells (Wassell et al., 1999; Winkler et al., 1999; Zarbin, 2004).

In vitro studies suggest that RPE lipofuscin is a photo-inducible generator of reactive oxygen species. Lipofuscin granules are continuously exposed to visible light and to high oxygen tension, which causes the production of reactive oxygen species and oxidative damage to RPE cells (Wassell et al., 1999; Winkler et al., 1999; Zarbin, 2004).

RPE lipofuscin accumulation can ultimately lead to the disruption of lysosomal integrity, induce lipid peroxidation, reduce the phagocytic capacity of RPE cells and ultimately lead to loss of RPE cells (Boulton et al., 1993; De La Paz and Anderson, 1992; Sundelin and Nilsson, 2001; Zarbin, 2004).

Consistent with the oxidative stress model, clinical studies on the use of antioxidants has shown that in patients with extensive intermediate drusen, supplementation with antioxidant vitamins and minerals reduces the risk of developing advanced AMD from 28% to 20% (Age related eye disease study research group, 2001).

2.2.3 Abnormal ECM production

With aging, various changes can happen to the extracellular matrix deposited within the Bruch’s membrane. It has been shown that there is a decline of laminin, fibronectin and type
IV collagen in the aging RPE basement membrane, particularly over the drusen (Pauleikhoff et al., 1999).

There is an age dependent increase in type I collagen within the Bruch’s membrane, with an increase in the thickness of the membrane from 2 micrometres at birth, to up to 6 micrometres in the elderly ages (Ramrattan et al., 1994). During aging, the membrane glycosaminglycans in Bruch’s membrane increase in size, and there is an increase in the heparan sulphate proteoglycan content of the membrane (Hewitt et al., 1989). Furthermore, glycation end products can accumulate within the Bruch’s membrane with aging, trapping other macromolecules (King and Brownlee, 1996; Schmidt et al., 2000).

RPE cells themselves are the source of many of these ECM molecules. Histologically, abnormal extracellular matrix can be found between the RPE cells and the basement membrane (basal laminar deposits) and external to the basement membrane within the collagenous layers of the membrane (basal linear deposits) (Bressler et al., 1994; Green and Enger, 2005). Drusen therefore can be a localized accentuation of these deposits in AMD (Bressler et al., 1994).

The increase in thickness and change in composition of the Bruch’s membrane in AMD can lead to a disruption of the exchange of molecules between choriocapillaris and the subretinal space (Starita et al., 1997).

In support of this model, it has been shown that the hydraulic conductivity of the Bruch’s membrane falls exponentially with age. Measurements have shown that most of the resistance to water flow lies in the inner collagenous layer of the Bruch’s membrane which is possibly due to accumulation of abnormal entrapped material within this plane (Starita et al., 1997). Therefore, the thickened Bruch’s membrane in AMD may lead to a diffusion barrier, leading to RPE and retinal dysfunction (Pauleikhoff et al., 1999; Remulla et al., 1995).

### 2.2.4 CNV formation

Multiple factors have been proposed as promoters of new blood vessels formation in wet AMD. Changes in the ECM is one of the abnormalities seen in AMD which can lead to the formation of new blood vessels. The mechanism by which this phenomenon occurs is not completely understood but is likely to be a multifactorial. The risk of CNV in AMD increases with the increase in Drusen. Some drusen components and advanced glycation end products stimulate the production of angiogenic factors (Lu et al., 1998; Mousa et al., 1999). The increased thickness of Bruch’s membrane can also lead to reductions in choriocapillary blood flow and hypoxia (Remulla et al., 1995). Hypoxia in turn can upregulate genes Ang-1 and Ang-2, with Ang-1 promoting maturation and stabilization of blood vessels, and Ang-2 conferring endothelial cell responsiveness to angiogenic factors (Hanahan, 1997; Maisonpierre et al., 1997). In addition, RPE cells are themselves known to produce angiogenic factors, such as VEGF, (Kim et al., 1999) which can lead to neovascularisation. High concentrations of VEGF and its receptors are found in CNV and RPE cells (Kliffen et al., 1997; Kvanta et al., 1996). Furthermore, anti-VEGF treatments prevent laser induced CNV formation in primate models of AMD (Krzystolik et al., 2002).

It has been shown that overexpression of VEGF in transgenic mice leads to the formation of aberrant choriocapillaries. However, these vessels are not capable of penetrating the intact Bruch’s membrane (Schwesinger et al., 2001). Therefore, damage to Bruch’s membrane due
to various factors in combination with the upregulation of VEGF, can synergistically lead to the choriocapillary CNVs penetrating the membrane and reaching the subretinal space (Schwesinger et al., 2001; Zarbin, 2004).

One of the molecules that has been studied extensively in our lab is a glycoprotein called tenascin C, known to be overexpressed in angiogenesis (Zagzag and Capo, 2002; Zagzag et al., 1996), neovascularisation and wound healing (Maseruka et al., 1997). Tenascin C deposition can occur in the Bruch’s membrane in wet AMD on the basal side of RPE cells (Fasler-Kan et al., 2005) and in association with CNVs in the pathological Bruch’s membrane (Nicolo et al., 2000). Tenascin C has been shown to prevent adhesion of RPE cells to extracellular matrix (Afshari et al. 2010). Therefore accumulation of this molecule associated with CNV formation may play an important role in RPE loss from the Bruch's membrane seen in AMD (Afshari et al 2010).

In summary, different pathological processes during aging and in AMD can lead to modifications in the Bruch’s membrane which ultimately becomes a less supportive environment for the RPE adhesion and function.

3. Experimental models available for studying wet AMD

3.1 In vitro and ex vivo models - Advantages vs disadvantages

In vitro models have allowed development of simplified systems to study processes involved in wet AMD. Most in vitro models have focused on the role of angiogenesis and isolation of Bruch’s membrane to assess adhesion and survival of RPE cells.

Tezel and Del priore first described methodology for accessing different layers of Bruch’s membrane to allow in vitro assessment of RPE adhesion at different levels of Bruch’s membrane. A combination of enzymatic treatment and mechanical techniques were used to expose each layer sequentially starting from the top basal lamina and moving to deeper structures. Using this technique, it was shown that deeper layers of Bruch’s membrane are less supportive of RPE attachment (Del priore et al 1998; Tezel TH 1999 FEB; Tezel TH 1999 March). RPE cell adhesion to Bruch’s membrane may play a detrimental role both in AMD and following RPE transplantation.

An alternative way of accessing Bruch’s membrane used in our lab is the water lysis technique (Afshari et al 2010). In this method, eye globes are dissected out and separated from their muscle attachments. The anterior chamber is then dissected away leaving the posterior chamber and retina and Bruch’s-choroid-sclera. Retinal layer is then carefully removed leaving the Bruch’s-choroid-sclera trilaminar structure which can be subsequently exposed to water. Exposure to water leads to lysis of endogenous RPE cells. Lysed RPE cells are then flushed away from the surface of Bruch’s membrane using a mini water jet. This procedure therefore results in formation of a denuded Bruch’s membrane which can allow further experiments such as transplanting exogenous RPE cells to assess adhesion and migration of the transplanted cells (Afshari et al 2010). The advantages of this technique is that minimal treatment of the tissue is required with preservation of natural Bruch’s membrane. In addition the preparation of the Bruch’s membrane for adhesion and migration assay is a short procedure. Immunostaining of both frozen sections and electron microscopy of the membranes following water treatment have confirmed complete removal
of endogenous RPE layer therefore creating a suitable environment for transplanting exogenous cells (Afshari et al 2010). However for assessment of adhesion on different layers such as deeper collagen layers of Bruch’s membrane, methodology by Tezel and Del priore et al can be used (Del priore et al 1998; Tezel TH 1999 FEB; Tezel TH 1999 March).

Although much has been learned from the use of eyes derived from experimental animals such as rats and rabbits, a major problem faced is the unique human age related changes and AMD related pathological processes that have been hard to recapitulate in animal models. Therefore recent attention has been on use of human derived Bruch’s membrane and ex vivo models whereby pathological or normal samples can be used from donors. A great advantage of this technique is that good methodology exists for isolation of layers of Bruch’s membrane, and eyes from various stages of the disease can be studied. A disadvantage of using human samples is the difficulty in obtaining high quality tissue before post mortem deterioration occurs.

3.2 In vivo models - Advantages vs disadvantages

In vivo animal models have been used widely in studying AMD. Creating animal models specific for AMD has been a difficult task to achieve. One of the older animal models used in AMD research is Royal College of Surgeons rats (RCS rats) where RPE cells are gradually lost over time along with photoreceptors. RCS rats have been used in RPE transplantation experiments widely to assess efficiency of transplanted cells in replacing the lost endogenous RPE cells and preventing photoreceptor loss (Li and Turner 1988). However these rats are a better model for studying retinitis pigmentosa and therefore may differ considerably with regards to pathology from AMD.

Another used animal model comprises of mechanically scratching the RPE layer. This allows creation of focal areas devoid of RPE cells allowing studying various transplantation or pharmacological treatments. Rabbits are used generally in this model (Philips 2003) due to bigger size of the eye globes allowing easier access.

None of the models above recapitulate the neovascularisation seen in wet AMD. However recently more models have emerged which reproduce the neovascularisation process. Some of these models use growth factors such as b-fibroblast growth factor (FGF) or vascular endothelial growth factor (VEGF) to induce the endothelial cells proliferation and migration to promote CNV formation in rats, rabbits and monkeys (Montezumas.R 2009, Edwards A. 2007, Lassota N 2008, Baba T 2010). Over the years different techniques have been used to deliver growth factors ranging from direct injections, lentiviral vectors, cells secreting growth factors or transgenic animals secreting the VEGF (Spilsbury 2000; julien 2008; Okamoto et al1997; Cui et al 2000).

Newer techniques which can stimulate CNV formation include injection of matrigel subretinally which allows a suitable environment for blood vessels to grow into (Cao J 2010). An alternative to this has been use of polyethylene glycol injections subretinally which leads to activation of complemet cascade and generation of VEGF leading to CNV formation in mouse (Lyzogubov et al 2011).

Multiple transgenic mice lines also have been created which produce CNV through different methods. One of such animal models is use of transgenic mice producing mitogen prokineticin 1 (Hpk1) which specifically stimulates fenestrated endothelial cells.
Introduction of this mitogen can lead to CNV formation from choriocapillaries (Tanaka N 2006). By generating transgenic mice expressing Hpk1 in retina, Tanaka et al were able to show that Hpk1 promotes development of CNV with no effect on retinal vasculature. Interestingly, these mice also show increased levels of lipofuscin which is also seen in AMD (Tanaka N 2006).

One of the most interesting examples of transgenic mice used in studying wet AMD is the ccr2/ccl2 transgenic mice which are unable to recruit macrophages to RPE layer and Bruch’s membrane. This leads to accumulation of C5a and Immunoglobulin G which in turn leads to stimulation of VEGF production (Ambati 2003; Takeda et al. 2009).

An alternative method of CNV formation is application of laser to generate a focal area of burn within the Bruch's membrane which in turn leads to CNV formation. This technique over the years has become one of the most standard and widely used techniques in studying wet AMD. Various laser treatments using krypton, argon and diode have all been able to induce CNV formation in mice, rats, pigs and monkeys (Dobi et al 1989; Frank et al 1989; Ryan et al. 1979; Saishin et al 2003). To initiate CNV formation using laser, it is necessary for RPE layer, Bruch’s membrane and the underlying choroid to be damaged by the laser to allow penetration and initiation of new blood vessel formation. The laser induced CNV formation is VEGF mediated, as different methods of blocking VEGF using peptides and antibodies in mice, rats and monkeys are all able to block the neovascularisation process (Hua J 2010; Goody RJ 2011).

4. Treatments available for AMD and their mode of action

4.1 Surgical and cellular transplantation/replacement

Since defects in Bruch’s membrane in age related macular degeneration leads to RPE loss, replacement of RPE cells by transplantation has been proposed as a technique to prevent secondary photoreceptor death. In the past two decades, studies in various animal models of retinal degeneration and RPE loss have shown that RPE cell replacement may be a feasible technique to prevent a secondary photoreceptor loss due to RPE damage (Lund et al., 2001).

Li et al in 1988 demonstrated that RPE transplantation in young neonatal and adult rats allows a repopulation of denuded areas on the Bruch’s membrane and prevent the photoreceptor degeneration in dystrophic RCS rat models of AMD (Liand Turner, 1988a, b). In separate studies, Castillo et al have shown that transplantation of adult young human RPE cells derived from cadaveric eye samples, into the dystrophic RCS rats can salvage the photoreceptor loss in this model (Castillo et al., 1997).

Furthermore, subretinal transplantation of the RPE cell line ARPE-19, the most widely used adult human RPE cell line, in dystrophic RCS rats can rescue the photoreceptors (Wang et al., 2005). Other animal models, such as rabbit models of RPE damage, showed that mechanical debridement of the Bruch’s membrane followed by autologous RPE transplantation leads to the repopulation of debrided Bruch’s membrane with preservation of photoreceptors (Phillips et al., 2003).

In humans patients with AMD, the formation of choroidal new vessels is part of the pathology of advanced wet AMD. The removal of CNVs has also been carried out in human
patients with AMD. This can be followed by autologous transplantation of RPE cells, either harvested from the periphery of the Bruch’s membrane which is not affected by the disease process (Binder et al., 2007), or from RPE cells from other donors (Algvere et al., 1994).

Algvere et al. in 1994 assessed the effect of human fetal RPE transplantation in 5 patients with AMD after the removal of CNVs. Human fetal RPE cells survived up to 3 months and covered the denuded areas of the Bruch’s membrane (Algvere et al., 1994).

Other studies have also assessed the effect of adult autologous transplantation of RPE cells in AMD. It has been shown that autologous transplantation following the removal of CNVs is a feasible technique and associated with some visual acuity improvement (Binder et al., 2004).

In 2007 MacLaren et al. carried out autologous transplantation of the RPE cells, following submacular CNV excision, and reported viable grafts at 6 months time point and some level of visual function improvement in some patients. However, the complications associated with the surgery remained high (MacLaren et al., 2007).

RPE transplantation has traditionally been carried out as cell suspension but, due to problems with RPE attachment to Bruch's membrane, more recently RPE-choroid sheets have been tried as a means of delivering RPE cells (Treumer et al. 2007). In 2011, Falkner-Radler et al., carried out a study comparing RPE cell suspension with that of RPE-choroid sheet transplantation. This study showed that anatomical and functional outcome in both cases were comparable with no significant difference between the two techniques in humans (Falkner-RadlerCl 2011).

Despite some improvements gained in the visual function, the results from the CNV removal combined with RPE transplantation, have not been as successful as those observed with animal models. This may be due to age related changes specific to human AMD which are absent in the animal models used in studying AMD and RPE transplantation.

RPE transplantation as a therapeutic technique faces major limitations, including poor adhesion of RPE cells when transplanted subretinally. Studies have shown that RPE cells require rapid adhesion to avoid apoptosis (Tezel and Del Priore, 1997, 1999). Therefore, there is a limited time period after subretinal injection during which RPE cells need to reattach before undergoing cell death.

The lack of adhesion following transplantation is likely to be multifactorial due to the molecular changes resulting from pathological age related changes in the membrane, and other changes contributed by the disturbance of normal architecture of the membrane from the surgery.

Various studies using ex vivo models have demonstrated major differences between RPE and Bruch's membrane in patients from different ages, emphasizing the important role of aging in the pathological process. Studies by Gullapalli et al. have shown that aged submacular human Bruch’s membrane does not support adhesion, survival and differentiation of fetal RPE cells effectively (Gullapalli et al., 2005). Multiple studies have shown that RPE cell adhesion to the Bruch’s membrane is reduced on aged membranes, when compared to the membrane derived from younger donors (Del Priore and Tezel, 1998; Tezel et al., 1999).

In addition to changes in adhesion, survival and differentiation, it has been shown that the capacity of RPE cells to phagocytose the shed outer segment of rod photoreceptors is
Reduced when RPE cells are seeded on aged membranes than the young membranes (Sun, et al., 2007).

These functional differences are further backed up by the changes in gene expression between RPE cells cultured on aged and young membranes. It has been shown that the RPE cells seeded on aged membranes up-regulate 12 genes and downregulate 8 genes compared to RPE cells cultured on membranes derived from young donors suggesting the differences between ages are also reflected at gene level (Cai and Del Priore, 2006).

Therefore, it is evident that there is a significant age-dependent decline in the Bruch’s membrane’s ability to support the RPE cell adhesion and function, and therefore RPE loss and dysfunction in AMD can be at least partially reflective of changes within the membrane. These changes in Bruch’s membrane therefore pose an obstacle for the transplanted RPE cells, which require fast attachment and adhesion, to survive post-transplantation.

In addition, data from our lab and others have shown that in wet AMD, there is increased deposition of a glycoprotein associated with neovascularisation. This glycoprotein named tenascin C is deposited on the upper layer of Bruch’s membrane. Using purified tenascin C, we were able to show that human RPE cells lack the necessary integrins to attach to surfaces coated with this glycoprotein and therefore deposition of this molecule in pathological AMD Bruch’s membrane further reduces the chance of adhesion. Using in vitro assays we were able to show that if RPE cells are engineered to express a necessary receptor called alpha9beta1 integrin for tenascin C, they are able to attach following transplantation to the wet AMD derived Bruch’s membrane where as in the absence of this receptor, control RPE cells were unable to attach to the membrane effectively (Afshari et al 2010).

In addition to changes mentioned above, surgical techniques used in removal of CNVs have been shown to damage the normal architecture of Bruch’s membrane. It is well established that surgical removal of CNVs in the wet AMD generally leads to excision of the basement membrane of the Bruch’s membrane (Grossniklaus et al., 1994). Tsukahara et al using ex vivo models of aged Bruch’s membrane have shown that the resurfacing of the Bruch’s membrane is highly dependent on whether the basement membrane is intact or removed. The adhesion of RPE cells was much higher on aged Bruch’s membrane if the basement membrane was not damaged and removed (Tsukahara et al., 2002). Therefore, one of the limitations of the CNV removal procedure is the iatrogenic removal of the laminin rich basement membrane, which reduces the chance of adhesion of RPE cells transplanted subsequently into the subretinal space.

In addition to the removal of the laminin rich basement membrane of Bruch’s membrane, the surgical procedures also lead to the exposure of deeper layers of the Bruch’s membrane. Various studies have assessed the adhesion rate and the survival of RPE cells on different layers of the Bruch’s membrane. They have revealed that RPE cell reattachment is the highest on the uppermost layers of the Bruch’s membrane which include basement membrane. As deeper layers are exposed, this adhesion rate decreases (Del Priore and Tezel, 1998). Thus, following CNV removal, depending on which layer of the Bruch’s membrane is exposed, the outcome of adhesion will differ which diminishes the chances of fast and efficient adhesion of the RPE cells following transplantation (Del Priore and Tezel, 1998).

RPE cells are known to attach to the human Bruch’s membrane through beta1 integrin-mediated interaction, with extracellular ligands such as laminin, fibronectin, vitronectin and
collagen IV (Ho and DelPriore, 1997). Tezel et al have demonstrated that laminin and fibronectin supported the adhesion of RPE cells best and prevented cellular apoptosis (Tezel and Del Priore, 1997). Since the upper most layers of the Bruch’s membrane are rich in laminin and fibronectin, removal of basement membrane combined with the exposure of deeper less adhesive substrates, limits adhesion following transplantation. Therefore, there is a great need for promoting cell adhesion post transplantation to allow resurfacing and seeding of the pathologically and surgically altered membranes. Multiple problems faced with transplantation therefore has lead to more attention on pharmacological and less invasive techniques to halt the CNV formation.

4.2 Photodynamic therapy and laser treatment

Laser photocoagulation is one of the techniques that was developed to treated neovascularisation problem in wet AMD. Since this technique leads to full thickness retinal burns, this can lead to loss of visual acuity if carried out in foveal region and therefore it is reserved for extrafoveal CNVs. In addition, there is a high rate of recurrence of CNVs following treatment with this method (Vedula SS and Krzystolik M 2011). However this technique is effective in reducing the progression of non-subfoveal CNVs compared to observation alone (Virgil 2007; Vedula SS and Krzystolik M 2011).

Photodynamic therapy on the other hand is a technique that works by injecting a photosensitive dye intravenously which preferentially binds to CNVs. On exposure of the eye to laser light, the dye can be activated leading to obliteration of the CNVs. This technique has the advantage of causing minimal trauma to normal choroid and membrane and the overlying retina. It therefore can be used for subfoveal lesions. The disadvantage with this technique is the necessity to repeat this procedure at least multiple times due to high rate of recurrence (TAP 1999; Vedula SS 2011).

4.3 Anti-VEGF monoclonal antibodies

One of the most recent approaches in battling wet AMD is the use of anti-VEGF monoclonal antibodies. Vascular endothelial growth factor has been shown to be involved in promoting formation of new blood vessels. The source of VEGF in AMD is believed to be the RPE cells themselves. Multiple studies have demonstrated presence of VEGF in RPE cells and its association with CNVs (Kim et al. 1999; Klifen 1997; Kvanata 1996). Although VEGF is necessary for neovascularisation, animal research shows that in the presence of intact normal Bruch’s membrane, blood vessels will not invade the subretinal area and therefore a pathological process must render the membrane permeable to invading growing new blood vessels in AMD setting (Schwesinger 2001). Regardless of this finding, use of blocking agents against VEGF or its receptor holds promise in halting neovascularisation.

Animal studies have shown that blocking VEGF using different approaches can halt the neovascularisation process. Multiple clinical trials have assessed efficacy and safety of anti-VEGF monoclonal antibodies which include Bevacizumab, ranibizumab, pegabtanib (Vedula SS and Krzystolik M 2011). A recent systematic review of randomised controlled trials compared recent trials using anti-VEGF in wet AMD. Pegabtanib and Ranibizumab were shown to be both effective in reducing the neovascularisation with improvements in visual acuity and quality of life (Vedula SS and Krzystolik M 2011). There are currently no
trials comparing these two drugs directly together. Bevacizumab, which also blocks VEGF and is considerably cheaper than its counterparts, has also been used off licence for treating wet AMD although originally it was licensed for colorectal carcinoma (Avery 2006, Emerson 2007). Although multiple studies have shown efficacy of this monoclonal antibody in reducing neovascularisation, the safety profile of this antibody is not as clear as other two (Mitchell P 2011).

5. Problems and challenges for future

With increasing aging population, the number of patients with AMD is likely to rise sharply. The projected number of advanced AMD cases is likely to rise by 50% by year 2020 (Friedman et al 2004). Therefore with increasing incidence of this condition, screening programs may be of value to allow early detection and treatment of this condition. This is of paramount importance as early detection has been shown to be associated with a better outcome and prognosis (Wong et al 2008).

With recent advances in cell transplantation and knowledge of stem cells, it may be possible that stem cell derived RPE cells can be used in the treatment of AMD (Lee and Maclaren 2011). Use of these cells may be of benefit as they have the potential to replace the lost cells and may not be hindered by the obstacles such as poor adhesion faced with cadaveric or donor derived RPE cells. For dry AMD, cell transplantation strategies are also undergoing clinical trials in several centres worldwide. Strategies to compare improve the survival and adhesion of transplanted cells to damaged Bruch's membrane are a key focus of our ongoing work.

Manipulation of integrins on RPE cells or genetic engineering of transplanted cells is a new field that holds promise in overcoming the obstacles faced in cell transplantation. Activating integrins by enhancing their function or introduction of new subunits of integrins into RPE cells have been shown to overcome the poor attachment and integration of RPE cells over Bruch's membrane (Afshari et al 2010; Fang et al 2009). It is therefore possible that with better understanding of RPE biology, adhesion and survival of cells following transplantation could be improved.

With the advent of the new therapies such as monoclonal anti-VEGF treatments, major advances have occurred in the treatment of wet AMD. At this point the challenges reside in wide access and affordable costs to allow early recognition and prevention of loss of vision at an early stage. Currently repeated injections of monoclonal antibodies limit their use in areas where access to such therapies is limited. With better understanding and experience of using such therapies, it is hoped that treatments with longer half lives and more affordable prices can be available to increasing aging population.

6. References


Age-related Macular Degeneration (AMD) is the leading cause of vision loss and blindness in the developed countries. In the past decade, great progress has been made in understanding the pathobiology and genetics of this blinding disease, as well as in finding new therapies for its treatment. These include the discovery of several genes that are associated with the risk of AMD, new anti-VEGF treatments for wet AMD and new imaging techniques to diagnose and monitor the AMD. All chapters in this book were contributed by outstanding research scientists and clinicians in the area of AMD. I hope this timely book will provide the basic scientists and clinicians with an opportunity to learn about the recent advances in the field of AMD.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: